Anthracycline Chemotherapy Benefit in HR+/HER2− Early-Stage Breast Cancer Treatment
After a diagnosis of early-stage hormone receptor–positive (HR+) and Read More
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky*, Read More
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024 GalleryAgendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrint® in Read More
What Is Chemotherapy?
Along with surgery or radiation therapy, chemotherapy is one Read More
